REVIEW ARTICLE

Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis

Yanyan Wu[1,2] · Hongyu Li[1] · Xiaozhong Guo[1] · Eric M. Yoshida[3] · Nahum Mendez-Sanchez[4] · Giovanni Battista Levi Sandri[5] · Rolf Teschke[6] · Fernando Gomes Romeiro[7] · Akash Shukla[8] · Xingshun Qi[1]

Abstract

Background and aims Coronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients.

Methods PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases were searched. The incidence of abnormal liver biochemical tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL), and albumin (ALB), was pooled. Risk ratio (RR) was calculated to explore the association of abnormal liver biochemical tests with severity and prognosis of COVID-19 patients.

Results Forty-five studies were included. The pooled incidence of any abnormal liver biochemical indicator at admission and during hospitalization was 27.2% and 36%, respectively. Among the abnormal liver biochemical indicators observed at admission, abnormal ALB was the most common, followed by GGT, AST, ALT, TBIL, and ALP (39.8%, 35.8%, 21.8%, 20.4%, 8.8%, and 4.7%). Among the abnormal liver biochemical indicators observed during hospitalization, abnormal ALT was more common than AST and TBIL (38.4%, 28.1%, and 23.2%). Severe and/or critical patients had a significantly higher pooled incidence of abnormal liver biochemical indicators at admission than mild and/or moderate patients. Non-survivors had a significantly higher incidence of abnormal liver biochemical indicators than survivors (RR = 1.34, $p = 0.04$).

Conclusions Abnormal liver biochemical tests are common in COVID-19 patients. Liver biochemical indicators are closely related to the severity and prognosis of COVID-19 patients.

Keywords COVID-19 · SARS-CoV-2 · Hepatic · Liver · Incidence · Risk

Abbreviations

COVID-19	Coronavirus disease 2019
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
ACE2	Angiotensin converting enzyme 2
MOF	Multiple organ failure
ARDS	Acute respiratory distress syndrome
NOS	Newcastle-Ottawa scale
RR	Risk ratio
MD	Mean difference
CI	Confidence interval
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
ALP	Alkaline phosphatase
GGT	Gamma-glutamyl transpeptidase
TBIL	Total bilirubin
ALB	Albumin
SIRS	Systemic inflammatory response syndrome
CYP3A4	Cytochrome P 450 3A4

Yanyan Wu, Hongyu Li, Xiaozhong Guo are Co-first authors.

✉ Xingshun Qi
xingshunqi@126.com

Extended author information available on the last page of the article

Introduction

Until May 6, 2020, coronavirus disease 2019 (COVID-19) has posed a serious threat to global public health with a total of 3,272,202 confirmed cases and 230,104 deaths documented in 212 countries [1]. Its pathogen is named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. Except for fever, cough, and dyspnea as the major clinical presentations [3], COVID-19 patients may also develop different degrees of liver injury [4, 5]. The major mechanism of liver injury in COVID-19 patients is thought to be the binding of SARS-CoV-2 to angiotensin converting enzyme 2 (ACE2) receptor [6], which is highly expressed in bile duct cells [7], and then damages bile duct cells, thereby resulting in abnormal liver biochemical tests reflected by elevated alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) [8]. In addition, liver injury in SARS-CoV-2 infection may be caused by either systemic inflammation response or drug hepatotoxicity, which is supported by the first autopsy pathological analysis of a COVID-19 patient showing moderate microvesicular steatosis and mild lobular and portal activity in the liver tissue [9]. Multiple organ failure (MOF) is another possible cause of liver injury in COVID-19 patients, as SARS-CoV-2 can cause acute respiratory distress syndrome (ARDS) and MOF, thereby leading to hepatic ischemia, which could be worsened by the use of vasopressor medications, and hypoxia reperfusion injury in critically ill patients [10, 11]. Indeed, evidence also suggested that critically ill patients have a higher proportion of liver enzyme abnormality than patients with mild disease [8].

It is important for physicians, especially hepatologists, to appreciate the epidemiology and potential risk of liver injury in COVID-19 patients [12, 13]. However, the data regarding abnormal liver biochemical tests in COVID-19 patients are often heterogeneous among studies, and assessing the risk of liver injury in such patients remains challenging. In this study, we have systematically collected the current evidence with two major objectives: (1) to achieve more generalizable conclusions regarding the incidence of abnormal liver biochemical tests in COVID-19 patients; and (2) to explore the relationships of abnormal liver biochemical indicators with the severity and prognosis of COVID-19 patients.

Methods

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. The MOOSE and PRISMA checklists are shown in the Supplementary Materials.

Search strategy

All published literature which reported liver biochemical tests in COVID-19 patients were identified via the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases. The search terms were ("2019 novel coronavirus-infected pneumonia" OR "COVID-19" OR "2019 novel coronavirus" OR "2019 novel coronavirus pneumonia" OR "severe acute respiratory syndrome coronavirus 2" OR "SARS-CoV-2" OR "novel coronavirus pneumonia") AND ("liver" OR "hepatic"). The last retrieval date was April 27, 2020.

Study selection

There was neither publication language nor publication status restriction. All eligible studies reported the incidence and/or risk factors of abnormal liver biochemical tests in COVID-19 patients. Exclusion criteria were as follows: (1) duplicates; (2) case reports, reviews or meta-analyses, guidelines, consensus, experimental or animal studies, comments or letters, notes, and correspondences; (3) irrelevant papers; (4) absence of detailed data; (5) duplicate study population.

Data extraction

Data extraction was performed by 2 investigators. The following data were extracted from the included studies: the first author, publication year, region, source of cases, enrollment period, cases with COVID-19, age, gender, history of pre-existing liver diseases, treatments, clinical outcomes, and liver biochemical tests at admission or during hospitalization. Liver biochemical indicators analyzed included alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALP, GGT, total bilirubin (TBIL), and albumin (ALB).

Study quality

The quality of cohort studies was assessed using the Newcastle–Ottawa Scale (NOS), which includes study selection (four items), comparability (two items), and exposure/outcome (three items). The highest score is 9 points, and a score of more than 6 points is considered high quality.

Definitions

The definition regarding the severity of COVID-19 patients was inconsistent among these included studies.

Among them, 36 studies employed the definitions from the Chinese practice guidelines regarding diagnosis and treatment of novel coronavirus pneumonia, in which patients were divided into four subtypes (mild, moderate, severe, and critical); 4 studies employed the definitions from the American Thoracic Society guidelines, in which patients were categorized into severe and non-severe types; and the remaining 5 studies did not clearly report the definition regarding the severity of COVID-19 patients. Therefore, as for the present systematic review, the severity of COVID-19 patients was mainly dependent upon the definitions from each individual study.

The time when liver biochemical indicators were measured during hospitalization was not strictly defined in the present systematic review, because it was not strictly or consistently defined among these included studies. Generally, liver biochemical indicators at admission refer to those measured at admission or within 24 h after admission; and liver biochemical indicators during hospitalization refer to those measured at any time during hospitalization.

Statistical analysis

All statistical analyses were performed using StatsDirect statistical software version 2.8.0 (StatsDirect Ltd., Sale, Cheshire, UK), STATA version 12.0 (Stata Corp., College Station, Texas, USA), and Review Manager software version 5.3 (Cochrane collaboration, the Nordic Cochrane Centre, Copenhagen, Denmark). First, the incidence of abnormal liver biochemical tests from each study were pooled, and the pooled proportion with 95% confidence interval (CI) was calculated. Second, we calculated the risk ratios (RRs) or mean differences (MDs) with 95% CIs. The meta-analyses were performed by using a random-effect model. Heterogeneity among the studies was also assessed. $I^2 > 50\%$ and/or $p < 0.1$ were considered to have statistically significant heterogeneity. Publication bias was assessed with Egger test. $p < 0.1$ was considered as a statistically significant publication bias. Subgroup analyses were performed according to the source of cases (single-center versus multiple-center), sample size (≥ 100 versus < 100), NOS (≥ 7 versus < 7), proportion of male ($\geq 50\%$ versus $< 50\%$), and proportion of patients with pre-existing liver disease ($\geq 10\%$ versus $< 10\%$). Meta-regression analyses employed the covariates that were the same as the strata of subgroup analyses, including the source of cases, sample size, NOS, proportion of male, and proportion of patients with pre-existing liver disease. Sensitivity analyses were conducted by sequentially

excluding one study at a time. These analyses were performed to explore the sources of heterogeneity among studies.

Results

Study selection

Overall, 2281 papers were identified via the 6 databases, and 11 papers were identified via a manual search. Finally, 45 studies were included in this meta-analysis (Fig. 1) [14–58].

Study characteristics

Characteristics of the included studies are summarized in Table 1. Among them, 30 studies [15, 16, 19, 21, 23, 25–30, 33–37, 39–41, 43–46, 49, 50, 52–56] were formally published as full texts, 9 studies [18, 24, 31, 32, 38, 42, 47, 48, 51] were published in press, and the remaining 6 studies [14, 17, 20, 22, 57, 58] were preprinted. The number of COVID-19 patients ranged from 18 to 1099 among these included studies. Nearly all of these included studies (44/45) were conducted in China, and the remaining one in Singapore; 33 [14–16, 18, 20–22, 24–26, 28–35, 38, 39, 41, 43–47, 49–52, 54, 56, 58] and 12 studies [17, 19, 23, 27, 36, 37, 40, 42, 48, 53, 55, 57] were single-center and multi-center studies, respectively. Treatment and clinical outcomes of COVID-19 patients are summarized in Supplementary Table 1.

Study quality

The NOS score ranged between 3 and 8 points. Eight studies [15, 16, 21, 23, 29, 36, 40, 50] were considered to be of high quality (Supplementary Table 2).

Incidence

The results of meta-analyses regarding the incidence of abnormal liver biochemical tests in COVID-19 patients are shown in Table 2.

Overall analyses

The pooled incidence of any abnormal liver biochemical indicator at admission was 27.2% (95% CI 19–36.3%). The pooled incidence of abnormal ALT, AST, ALP,

Fig. 1 Flow chart of study selection

GGT, TBIL, and ALB at admission was 20.4% (95% CI 16.8–24.3%), 21.8% (95% CI 17.6–26.3%), 4.7% (95% CI 1.8–8.9%), 35.8% (95% CI 17.8–56.1%), 8.8% (95% CI 5.5–12.8%), and 39.8% (95% CI 30.6–49.5%), respectively.

The pooled incidence of any abnormal liver biochemical indicator during hospitalization was 36% (95% CI 12.3–57.1%). The pooled incidence of abnormal ALT, AST, and TBIL during hospitalization was 38.4% (95%

Table 1 An overview of included papers regarding COVID-19

First author (year)	Country	Source of cases	Enrollment period	Sample size (n)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Zhang (2020) [14]	China	Renmin Hospital, Wuhan University	2020.01.11–2020.02.10	82	72.5 (65–80)	54 (65.9%)	2 (2.4%)	64/82[d]	Abnormal ALT 22 (30.6%); Abnormal AST 44 (61.1%); Abnormal TBIL 22 (30.6%); Abnormal ALB 56 (77.8%)
Li (2020) [15]	China	Guangzhou Eighth People's Hospital	2020.01.24–2020.02.25	82	44.8 ± 15.6[b]	48 (58.5%)	NA	38/82	Abnormal ALT 12 (14.6%); Abnormal AST 10 (12.1%); Abnormal TBIL 11 (13.4%); Abnormal ALB 36 (43.9%)
Li (2020) [16]	China	Zhuzhou Central Hospital	2020.01.20–2020.02.27	80	47.5 (3–90)[a]	40 (50%)	3 (3.8%)	NA	NA
Qi (2020) [17]	China	Three designated hospitals of Chongqing	2020.01.19–2020.02.16	267	48 (35–65)	149 (55.8%)	NA	NA	Abnormal ALT 20 (7.5%); Abnormal AST 19 (7.1%); Abnormal TBIL 6 (2.2%); Abnormal ALB 63 (23.6%)
Sun (2020) [18]	China	Tongji Hospital, Huazhong University of Science and Technology	2020.02.09–2020.02.27	51	NA	NA	7 (13.7%)	29/51	Abnormal ALT 24 (47.1%); Abnormal AST 24 (47.1%); Abnormal ALB 26 (51%); Abnormal GGT 18 (35.3%); Abnormal ALP 7 (13.7%)
Guan (2020) [19]	China	552 Hospitals	Till Jan. 29, 2020	1099	47 (35–58)	637 (58.1%)	23 (2.1%)	NA	Abnormal AST 168 (22.2%); Abnormal ALT 158 (21.3%); Abnormal TBIL 76 (10.5%)
Wang (2020) [20]	China	The Public Health Treatment Center of Changsha	2020.01.17–2020.02.20	242	45 (1–84)[a]	119 (49.2%)	12 (5%)	NA	NA
Huang (2020) [21]	China	Jinyintan Hospital	2019.12.16–2020.01.02	41	49 (41–58)	30 (73%)	1 (2.4%)	NA	Abnormal AST 15 (36.6%)

Table 1 (continued)

First author (year)	Country	Source of cases	Enrollment period	Sample size (n)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Huang (2020) [22]	China	Fifth Hospital of Wuhan	2020.01.21–2020.02.10	36	69.22 ± 9.64[b]	25 (69.44%)	NA	22/36	Abnormal ALT 4 (13.3%); Abnormal AST 18 (58.1%); Abnormal TBIL 4 (12.9%); Abnormal ALB 25 (80.6%)
Jin (2020) [23]	China	Designated hospitals in Zhejiang	2020.01.17–2020.02.08	651	NA	301 (46.2%)	25 (3.8%)	64/651[d]	NA
Wen (2020) [24]	China	Fifth Medical Center of the PLA General Hospital	2020.01.20–2020.02.08	46	41.8 ± 16.3[b]	27 (58.7%)	NA	8/46	Abnormal ALT 8 (17.4%); Abnormal AST 5 (10.9%); Abnormal ALB 1 (2.2%)
Yang (2020) [25]	China	Nanjing Public Health Center	2020.01.01 to date	57	37 (5–97)[a]	29 (50.9%)	NA	9/57	Abnormal ALT 9 (15.8%); Abnormal AST 4 (7%)
Cheng (2020) [26]	China	Jinyintan Hospital	2020.01.01–2020.02.06	463	51 (43–60)	244 (52.7%)	22 (4.8%)	NA	Abnormal ALT 114 (24.6%); Abnormal TBIL 19 (4.1%); Abnormal ALB 125 (27%)
Liu (2020) [27]	China	Seven designated hospitals of China	2020.01.23–2020.02.03	32	38.50 (26.25–45.75)	20 (62.5%)	1 (3.1%)	NA	Abnormal ALT[e] 9 (28.1%); Abnormal AST[e] 2 (6.25%)
Liu (2020) [28]	China	The Affiliated Hospital of Jianghan University	2020.01.10–2020.01.30	30	35 ± 8[b]	10 (33%)	NA	7/30	Abnormal AST and ALT 7 (23.3%)
Xu (2020) [29]	China	Fifth People's Hospital of Xinyang	2020.01.22–2020.01.29	23	46 (40.5–52)	15 (65.2%)	NA	5/23	Abnormal ALT 5 (21.7%); Abnormal AST 5 (21.7%)
Qian (2020) [30]	China	Shanghai Public Health Clinical Center	2020.01.20–2020.02.24	324	51 (36–64)	167 (51.5%)	90 (27.8%)	NA	Abnormal ALT 51 (15.7%); Abnormal TBIL 21 (6.5%); Abnormal ALB 136 (42%); Abnormal ALP 4 (1.2%)

Table 1 (continued)

First author (year)	Country	Source of cases	Enrollment period	Sample size (n)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Zhao (2020) [31]	China	The Fourth People's Hospital of Nanning	2020.01.22–2020.02.05	28	44.5 (11–68)[a]	11 (39.3%)	NA	NA	Abnormal AST 3 (10.7%); Abnormal ALT 6 (21.4%)
Wang (2020) [32]	China	Tongji Hospital, Huazhong University of Science and Technology	2020.01.10–2020.02.14	333	NA	NA	12 (3.6%)	89/333 43/333[d]	Abnormal ALT or AST 89 (26.7%); Abnormal TBIL[c] 13 (3.9%); Abnormal ALB 82 (24.6%)
Zhong (2020) [33]	China	Hainan General Hospital	2020.01.21–2020.02.10	62	(51.8±13.5)[b]	40 (64.5%)	NA	10/52	Abnormal ALT 6 (11.5%); Abnormal AST 4 (7.7%); Abnormal ALB 8 (15.4%)
Xiang (2020) [34]	China	The First Affiliated Hospital of Nanchang University	2020.01.21–2020.01.27	49	42.9 (18–78)	33 (67.3)	6 (12.2%)	NA	NA
Wan (2020) [35]	China	Chongqing University Three Gorges Hospital	2020.01.23–2020.02.08	135	47 (36–55)	72 (53.3%)	2 (1.5%)	NA	Abnormal AST 30 (22.2%)
Xu (2020) [36]	China	Seven designated tertiary hospitals of Zhejiang	2020.01.10–2020.01.26	62	41 (32–52)	35 (56%)	7 (11.3%)	NA	Abnormal AST 10 (16.1%)
Yang (2020) [37]	China	Three tertiary hospitals of Wenzhou	2020.01.17–2020.02.10	149	45.11±13.35[b]	81(54.4%)	NA	NA	Abnormal AST 27 (18.1%); Abnormal ALT 18 (12.1%); Abnormal TBIL 4 (2.7%); Abnormal ALB 9 (6%)
Yao (2020) [38]	China	Tangdu Hospital	2020.01.21–2020.02.21	40	53.87±15.84[b]	25 (62.5%)	3 (7.5%)	0 22/40[d]	Abnormal ALT[c] 21 (52.5%); Abnormal AST[c] 16 (40%); Abnormal TBIL[c] 10 (25%)
Ma (2020) [39]	China	Wuhan Children's Hospital	NA	115	51 day–15 year	74 (63.5%)	NA	NA	Abnormal ALT 11 (9.6%); Abnormal TBIL 3 (2.6%)

Table 1 (continued)

First author (year)	Country	Source of cases	Enrollment period	Sample size (n)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Young (2020) [40]	Singapore	Four hospitals in Singapore	2020.01.23–2020.02.03	18	47 (31–73)[b]	9 (50%)	NA	3/18[d]	NA
Zhou (2020) [41]	China	The First People's Hospital of Xianning City	2019.12–2020.02	107	NA	NA	NA	NA	Abnormal ALT 25 (23%); Abnormal AST 23 (21%)
Zhao (2020) [42]	China	The Second Affiliated Hospital of Anhui Medical University and Suzhou Municipal Hospital in Anhui	2020.01.23–2020.02.05	19	48 (27–56)	11 (57.9%)	1 (5.3%)	NA	Abnormal AST 5 (27.8%); Abnormal ALT 5 (27.8%); Abnormal GGT 8 (44.4%)
Du (2020) [43]	China	Wuhan Pulmonary Hospital	2019.12.25–2020.02.07	179	57.6 ± 13.7[b]	97 (54.2%)	NA	57/179	Abnormal AST 57 (31.8%)
Wang (2020) [44]	China	Renmin Hospital of Wuhan University	2020.01.01–2020.02.06	339	69 (65–76)	166 (49%)	2 (0.6%)	96/334	NA
Xie (2020) [45]	China	Jinyintan Hospital	2020.02.02–2020.02.23	79	60 (48–66)	44 (55.7%)	NA	NA	Abnormal ALT 25 (31.6%); Abnormal AST 28 (35.4%); Abnormal TBIL 4 (5.1%)
Pan (2020) [46]	China	Wuhan Hanan Hospital, Wuhan Union Hospital, and Huanggang Central Hospital	2020.01.18–2020.02.28	204	52.91 ± 15.98[b]	107 (52.5%)	2 (1.9%)	NA	Abnormal ALT 27 (13.2%); Abnormal AST 22 (10.8%)

Table 1 (continued)

First author (year)	Country	Source of cases	Enrollment period	Sample size (n)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Cai (2020) [47]	China	The Third People's Hospital of Shenzhen	2020.01.11–2020.02.21	417	47 (34–60)	198 (47.5%)	21 (5%)	192/417 318/417[d]	Abnormal ALT 54 (12.9%); Abnormal AST 76 (18.2%); Abnormal TBIL 96 (23%); Abnormal ALP 16 (3.8%); Abnormal GGT 68 (16.3%); Abnormal ALT 187 (44.8%)[c]; Abnormal AST 150 (36%)[c]; Abnormal TBIL 204 (48.9%)[c]; Abnormal ALP 32 (7.7%)[c]; Abnormal GGT 155 (37.2%)[c]
Sun (2020) [48]	China	Designated hospitals in Nanyang City	2020.01.24–2020.02.16	150	45 ± 16[b]	67 (44.7%)	1 (0.6%)	NA	Abnormal ALT 24 (16%); Abnormal AST 15 (10%); Abnormal TBIL 3 (2%)
Zheng (2020) [49]	China	North Hospital of Changsha first Hospital	2020.01.17–2020.02.07	161	45 (33.5–57)	80 (49.7%)	4 (2.5%)	NA	Abnormal ALT 13 (8.1%); Abnormal AST 22 (13.7%); Abnormal TBIL 9 (5.6%)
Zhang (2020) [50]	China	Wuhan Xinzhou District People's Hospital	2020.01.16–2020.02.25	95	49 (39–58)	53 (55.8%)	NA	NA	Abnormal ALT 52 (54.7%)[c]; Abnormal AST 45 (47.4%)[c]
Zhang (2020) [51]	China	Zhongnan Hospital of Wuhan University	2020.01.18–2020.02.22	115	49.52 ± 17.06[b]	49 (42.60%)	NA	NA	Abnormal ALT 11 (9.6%); Abnormal AST 17 (14.8%); Abnormal TBIL 8 (6.96%); Abnormal ALP 6 (5.21%); Abnormal GGT 15 (13%); Abnormal ALB 63 (54.78%)

Table 1 (continued)

First author (year)	Country	Source of cases	Enrollment period	Sample size (*n*)	Age, years Median (IQR)	Male No. (%)	History of liver diseases No. (%)	Any abnormal liver biochemical indicator at admission or during hospitalization	Abnormal liver biochemical indicator at admission or during hospitalization No. (%)
Fang (2020) [52]	China	Infectious Hospital of Anhui Provincial Hospital	2020.01.22–2020.02.19	79	45.1±16.6[b]	45 (57%)	3 (3.8%)	NA	Abnormal ALT 12 (15.2%); Abnormal AST 9 (11.4%); Abnormal TBIL 20 (25.3%)
Li (2020) [53]	China	Designated hospitals in Bozhou	2020.02.01–2020.02.12	28	42.2±14.9[b]	15 (53.6%)	NA	NA	Abnormal ALT 23 (82.1%); Abnormal AST 14 (50%); Abnormal GGT 23 (82.1%); Abnormal TBIL 2 (7.1%)
Wang (2020) [54]	China	Xixi Hospital in Hangzhou	2020.01.23–2020.02.24	72	NA	32 (44.4%)	NA	17/72	NA
Yuan (2020) [55]	China	Chongqing Public Health Medical Treatment Center	2020.01.24–2020.02.23	223	46.5±16.1[b]	106 (47.5%)	8 (3.6%)	NA	Abnormal ALT 42 (18.8%); Abnormal AST 32 (14.3%)
Bai (2020) [56]	China	Wuhan Union Hospital	2020.01.29–2020.02.26	58	62.12±12.95[b]	28 (48.3%)	NA	NA	Abnormal ALT 32 (55.2%); Abnormal AST 25 (43.1%); Abnormal ALB 43 (74.1%)
Huang (2020) [57]	China	Ten designated hospitals in Jiangsu	2020.01.22–2020.02.10	221	45 (33.5–56)	126 (57%)	6 (2.7%)	NA	NA
Li (2020) [58]	China	Beijing You'an Hospital	2020.01.21–2020.02.29	85	49 (36–64)	47 (55.3%)	6 (7%)	21/85 12/85[d]	Abnormal ALT 21 (24.7%); Abnormal ALT 12 (14.1%)[c]; Abnormal AST 12 (14.1%)[c]

ALT alanine aminotransferase, *AST* aspartate aminotransferase, *ALP* alkaline phosphatase, *GGT* gamma-glutamyl transpeptidase, *TBIL* total bilirubin, *ALB* albumin, *NA* not available

[a]Median (range)

[b]Mean±SD

[c]Liver biochemical indicator during hospitalization

[d]Proportion of any abnormal liver biochemical indicator during hospitalization

Table 2 Incidence of abnormal liver biochemical indicator: results of meta-analyses

Groups	No. studies	Range (%)	Pooled proportion using random-effects model	Heterogeneity		Publication bias
				I^2	p	Egger:bias
Any abnormal liver biochemical indicator at admission	12	0–61.1	0.272 (95% CI, 0.190–0.363)	88.6% (95% CI, 82.3–92%)	< 0.0001	4.611 (95% CI, – 0.262 to 9.483) $p = 0.0612$
Abnormal ALT at admission	28	7.5–55.2	0.204 (95% CI, 0.168–0.243)	88% (95% CI, 84.1–90.5%)	< 0.0001	2.650 (95% CI, 0.505–4.795) $p = 0.0174$
Abnormal AST at admission	28	7–61.1	0.218 (95% CI, 0.176–0.263)	89.3% (95% CI, 86.2–91.5%)	< 0.0001	2.890 (95% CI, 0.740–5.039) $p = 0.0104$
Abnormal ALP at admission	4	1.2–13.7	0.047 (95% CI, 0.018–0.089)	81.6% (95% CI, 28.9–91.1%)	0.001	2.7486 (95% CI, – 1.591 to 7.088) $p = 0.1124$
Abnormal GGT at admission	5	13–82.1	0.358 (95% CI, 0.178–0.561)	94.2% (95% CI, 90–96.2%)	< 0.0001	5.229 (95% CI, – 3.173 to 13.631) $p = 0.142$
Abnormal TBIL at admission	16	2.0–30.6	0.088 (95% CI, 0.055–0.128)	92.1% (95% CI, 89.2–93.9%)	< 0.0001	3.183 (95% CI, 0.029–6.338) $p = 0.0482$
Abnormal ALB on admission	16	2.2–80.6	0.398 (95% CI, 0.306–0.495)	96.1% (95% CI, 95.2–96.8%)	< 0.0001	8.819 (95% CI, 2.302–15.335) $p = 0.0116$
Any abnormal liver biochemical indicator during hospitalization	7	9.8–78.0	0.360 (95% CI, 0.118–0.648)	99.2% (95% CI, 99–99.3%)	< 0.0001	7.738 (95% CI, – 13.782 to 29.258) $p = 0.3978$
Abnormal ALT during hospitalization	5	14.1–54.7	0.384 (95% CI, 0.242–0.537)	91.3% (95% CI, 82.5–94.6%)	< 0.0001	– 0.620 (95% CI, – 14.725 to 13.486) $p = 0.8977$
Abnormal AST during hospitalization	5	6.3–47.4	0.281 (95% CI, 0.159–0.422)	90.6% (95% CI, 80.5–94.3%)	< 0.0001	– 1.705 (95% CI, – 17.062 to 13.651) $p = 0.7471$
Abnormal TBIL during hospitalization	3	3.9–48.9	0.232 (95% CI, 0.006–0.642)	99.2% (95% CI, 98.9–99.3%)	< 0.0001	NA NA

ALT alanine aminotransferase, *AST* aspartate aminotransferase, *ALP* alkaline phosphatase, *GGT* gammaglutamyltranspeptidase, *TBIL* total bilirubin, *ALB* albumin, *NA* not available, — the results cannot be calculated

CI 24.2–53.7%), 28.1% (95% CI 15.9–42.2%), and 23.2% (95% CI 6–64.2%), respectively.

Subgroup analyses

The results of subgroup analyses are summarized in Supplementary Table 3. The heterogeneity remained statistically significant in all subgroup analyses.

Meta-regression analyses

The results of meta-regression analyses are summarized in Supplementary Table 4. As for any abnormal liver biochemical indicator observed at admission, meta-regression analyses indicated that the source of cases ($p = 0.000$) might be a potential source of heterogeneity. As for abnormal ALT observed at admission, meta-regression analyses indicated that the sample size ($p = 0.019$) might be the potential source of heterogeneity. As for any abnormal liver biochemical indicator observed during hospitalization, meta-regression analyses indicated that the proportion of patients with pre-existing liver disease ($p = 0.028$) might be a potential source of heterogeneity. However, no source of heterogeneity could be identified for other liver biochemical indicators observed at admission or during hospitalization.

Sensitivity analyses

Sensitivity analyses did not identify any study as the potential source of heterogeneity.

Risk factors

Non-severe versus severe according to the American Thoracic Society guideline

Two studies [17, 19] compared the incidence of abnormal ALT, AST, and TBIL at admission between severe and non-severe patients. Meta-analyses demonstrated that severe patients had a significantly higher incidence of abnormal AST at admission (RR = 2.91, 95% CI 1.36–6.22; $p = 0.006$). The incidence of abnormal ALT (RR = 2.32, 95% CI 0.78–6.88; $p = 0.13$) and TBIL (RR = 1.95, 95% CI 0.68–5.58; $p = 0.21$) at admission were not significantly different between severe and non-severe patients.

Mild and moderate versus severe and critical according to the Chinese practice guideline

Only one study [38] compared the incidence of any abnormal liver biochemical indicator at admission between mild and moderate patients versus severe and critical patients, and demonstrated that severe and critical patients had a significantly higher incidence of any abnormal liver biochemical indicator at admission (RR = 2.78, 95% CI 1.28–6.06; $p = 0.01$). Three studies [49, 51, 55] compared the incidence of abnormal ALT at admission between mild and moderate patients versus severe and critical patients, and demonstrated that severe and critical patients had a significantly higher incidence of abnormal ALT at admission (RR = 3.03, 95% CI 1.76–5.23; $p < 0.0001$). Four studies [35, 49, 51, 55] compared the incidence of abnormal AST at admission between mild and moderate patients versus severe and critical patients, and demonstrated that severe and critical patients had a significantly higher incidence of abnormal AST (RR = 3.84, 95% CI 2.53–5.82; $p < 0.00001$) at admission. Two studies [49, 51] compared the incidence of abnormal TBIL at admission between mild and moderate patients versus severe and critical patients, and demonstrated that severe and critical patients had a significantly higher incidence of abnormal TBIL at admission (RR = 3.16, 95% CI 1.24–8.09; $p = 0.02$).

Eight studies [16, 20, 30, 35, 49, 51, 55, 57] compared the ALT level at admission between mild and moderate patients versus severe and critical patients. Meta-analyses demonstrated that ALT level was significantly higher in severe and critical patients than in mild and moderate patients (MD = 7.64, 95% CI 1.94–13.35; $p = 0.009$).

Seven studies [16, 20, 30, 35, 49, 51, 55] compared the AST level at admission between mild and moderate patients versus severe and critical patients. Meta-analyses demonstrated that AST level was significantly higher in severe and critical patients than in mild and moderate patients (MD = 13.20, 95% CI 7.57–18.82; $p < 0.00001$). Seven

studies [20, 30, 35, 49, 51, 55, 57] compared the TBIL level at admission between mild and moderate patients versus severe and critical patients. Meta-analyses demonstrated that TBIL level was lower in severe and critical patients than in mild and moderate patients (MD = − 0.22, 95% CI − 5.08 to 4.63; $p = 0.93$). Five studies [16, 30, 35, 55, 57] compared the ALB level at admission between mild and moderate patients versus severe and critical patients. Meta-analyses demonstrated that ALB level was significantly lower in severe and critical patients than in mild and moderate patients (MD = − 4.84, 95% CI − 6.68 to − 3.00; $p < 0.00001$).

Moderate versus severe and critical according to the Chinese practice guideline

Only one study [18] compared the incidence of any abnormal liver biochemical indicator at admission between moderate patients versus severe and critical patients, and demonstrated that severe and critical patients had a significantly higher incidence of any abnormal liver biochemical indicator at admission (RR = 1.91, 95% CI 1.17–3.1; $p = 0.009$).

Three studies [15, 34, 52] compared the ALT, AST, TBIL and ALB levels at admission between moderate patients and severe and critical patients. Meta-analyses demonstrated that the ALT (MD = 9.76, 95% CI 4.64–14.89; $p = 0.0002$), AST (MD = 6.32, 95% CI 2.90–9.74; $p = 0.0003$) and TBIL (MD = 3.14, 95% CI 1.14–5.14; $p = 0.002$) levels were significantly higher in severe and critical patients than in moderate patients, and the ALB level was significantly lower in severe and critical patients (MD = − 7.30, 95% CI − 8.69 to − 5.90; $p < 0.00001$).

Moderate versus severe according to the Chinese practice guideline

Five studies [26, 28, 29, 45, 54] compared the ALT and AST levels at admission between moderate and severe patients. Meta-analyses demonstrated that the ALT (MD = 11.99, 95% CI − 3.59 to 27.57; $p = 0.13$) and AST (MD = 10.30, 95% CI 0.11–20.49; $p = 0.05$) levels were higher in severe patients than in moderate patients. Three studies [26, 28, 54] compared the ALB level at admission between moderate and severe patients. Meta-analyses demonstrated that ALB level was significantly lower in severe patients than in moderate patients (MD = -4.62, 95% CI − 8.12 to − 1.13; $p = 0.01$). Two studies [26, 45] compared the TBIL level at admission between moderate and severe patients. Meta-analyses demonstrated that the TBIL level was lower in severe patients than in moderate patients (MD = − 0.12, 95% CI − 0.87 to 0.62; $p = 0.75$).

At admission versus during hospitalization

Two studies [32, 47] compared the ALT level detected at admission versus during hospitalization, and demonstrated that the ALT level detected during hospitalization was significantly higher than that obtained at admission (MD = 20.30, 95% CI 16.51–24.06; $p < 0.00001$).

The first week after admission versus the second week after admission

Only one study [38] compared the ALT level at the first week after admission versus the second week after admission, and demonstrated that ALT level detected at the second week after admission was significantly higher than that detected at the first week after admission (MD = 130.75, 95% CI 116.14–145.36; $p < 0.00001$).

Number of drug products combined

Only one study [38] compared the proportion of drug products ≥ 3 between patients with liver injury and those with normal liver biochemistry, and demonstrated that the proportion of drug products ≥ 3 was significantly higher in patients with liver injury than in those with normal liver biochemistry (RR = 9.00, 95% CI 1.28–63.26; $p = 0.03$).

Effect of liver biochemical indicators on prognosis of COVID-19 patients

Survivors versus non-survivors

Three studies [43, 44, 50] compared the incidence of any abnormal liver biochemical indicator between survivors versus non-survivors. Meta-analyses demonstrated that non-survivors had a significantly higher incidence of any abnormal liver biochemical indicator (RR = 1.34, 95% CI 1.02–1.77; $p = 0.04$).

With versus without composite endpoint

Two studies [19, 50] compared the incidence of abnormal ALT and AST between patients who achieved the composite endpoint versus those who did not achieve the composite endpoint. Both of them employed the same composite endpoint defined as admission to the ICU, mechanical ventilation, or death. Meta-analyses demonstrated that patients who achieved the composite endpoint had a significantly higher incidence of abnormal ALT (RR = 1.96, 95% CI 1.54–2.49; $p < 0.00001$) and AST (RR = 2.30, 95% CI 1.81–2.92; $p < 0.00001$).

Discussion

Our study suggested that the pooled incidence of any abnormal liver biochemical indicator detected during hospitalization seemed to be higher than that detected at admission (36% versus 27.2%). Except for the disease progression of COVID-19 during hospitalization, this might be partly due to the toxicity of drugs used during hospitalization. Patients are often given empirical antiviral therapy for COVID-19 after admission, of which some can be potentially hepatotoxic. At the time of this writing, recent studies have reported that lopinavir might be potentially effective against SARS-CoV-2 [59], but lopinavir/ritonavir is mainly metabolized by cytochrome P 450 3A4 (CYP3A4) enzymes in the liver, which is likely to cause elevated serum transaminases [60]. In addition, some patients may be treated with antipyretic agents during hospitalization, of which most contain acetaminophen that can be hepatotoxic in high doses and/or combination with other drugs and even cause liver failure [61].

Among the abnormal liver biochemical indicators observed at admission, abnormal ALB (39.8%) was the most frequent, followed by abnormal GGT (35.8%), AST (21.8%), ALT (20.4%), TBIL (8.8%), and ALP (4.7%). Decreased ALB level is usually considered to indicate that the synthetic function of the liver be damaged to some extent. However, a decline of ALB level may be related to the disease severity of COVID-19, as COVID-19 can cause pulmonary exudation, thereby leading to abnormal ALB distribution, and an insufficient intake of nutrients or impairment of normal utilization/metabolism of nutrients may also decrease the ALB level in COVID-19 patients. SARS-CoV-2 is prone to damage bile duct cells where the ACE2 is highly expressed [7]. Thus, abnormal GGT and ALP levels should have been more common. However, in the settings of liver injury, the de-differentiation and proliferation of ACE2-expressing bile duct epithelial cells are involved in liver tissue repair, and some newborn hepatocytes retain the characteristics of ACE2 expression and may be susceptible to SARS-CoV-2 [62], thereby affecting hepatocytes and presenting with abnormal AST and ALT levels. Both ALP and GGT are considered as cholangiocyte-related enzymes, but the pooled incidence of abnormal ALP seems to be remarkably higher than that of abnormal GGT (35.8% versus 4.7%). This counter-intuitive phenomenon may be attributed to a difference in the distribution of ALP and GGT. ALP is present in bile duct, bone, intestine, kidney, and placenta, while GGT is widely distributed in the cell membranes of many tissues, such as bile duct, kidney, pancreas, gallbladder, spleen, heart, brain, and seminal vesicle. Thus, GGT, as an indicator of bile duct injury, may be less sensitive than ALP.

Severe and critical COVID-19 patients and non-survivors are more prone to have abnormal liver biochemistry. This finding might be explained by several points, as follows. First, inflammatory factor storm is suspected to be associated with abnormal liver biochemistry in severe and critical COVID-19 patients. It has been recognized that the occurrence of MOF is mainly associated with the sudden initiation of an inflammatory storm in the critically ill patients [63]. The release of numerous inflammatory cytokines induces ARDS and systemic inflammatory response syndrome (SIRS) and subsequently causes hypoxia in the body, thereby leading to an injury in lung, liver, myocardium, and kidney. This may be aggravated by the use of vasopressor drugs to maintain blood pressure in an ICU setting. Second, hepatic ischemia and hypoxia reperfusion dysfunction may be one of the main mechanisms of liver injury in severe and critical COVID-19 patients. COVID-19 patients often have varied degrees of hypoxemia, of whom more than 40% need to receive oxygen therapy [19]. COVID-19-related complications include ARDS, SIRS, and MOF, which may cause hepatic ischemia and hypoxia reperfusion dysfunction. Both in vivo and in vitro models of liver ischemia and hypoxia suggested that liver cell death and inflammatory cell infiltration could be caused by ischemia and hypoxia [11]. Meanwhile, oxygen reduction and lipid accumulation in liver tissue during shock and hypoxic conditions may further promote the release of multiple inflammatory factors and then lead to liver injury [64]. Third, drug toxicity may contribute to liver damage in severe and critical COVID-19 patients. Compared with patients experiencing a mild or moderate clinical course, severe and critical patients require longer duration of antiviral therapy and multiple drugs combined. Our findings found that the number of drugs products ≥ 3 might be related to liver injury. Additionally, it has been reported that antiviral medications (lopinavir/ritonavir, arbidol, hydroxychloroquine), antipyretics (acetaminophen), antibiotics (macrolides, quinolones), and traditional Chinese medicine can cause liver damage [60, 65–67]. Also, some critical patients would be treated with steroids, which are mainly metabolized in the liver and could cause mild hepatotoxicity. In the setting of steroids combined with HIV protease inhibitors (such as lopinavir), the risk of liver damage could be further increased [68]. Notably, at the beginning of the COVID-19 crisis, in the complete absence of known antiviral/disease modulating medications, many drugs and combinations of drugs, which would have been previously considered for use only in a controlled experimental setting, may have been used empirically in clinical practice. Fourth, our subgroup analysis suggested that the incidence of any abnormal liver biochemical indicator at admission seemed to be higher in the subgroup where the proportion of pre-existing liver disease was ≥ 10% than in the subgroup where the proportion of re-existing liver disease was < 10%. This finding suggests that COVID-19 patients with pre-existing liver diseases may be more prone to have abnormal liver biochemical indicators and that monitoring liver function should be more intensive in such patients. Notably, this may not be a direct consequence of pre-existing liver diseases, but related to the dysfunction of innate immune response against the virus [69].

Our study has several limitations. First, the heterogeneity remained statistically significant in most of our meta-analyses. Despite this, we performed subgroup analyses, meta-regression analyses, and sensitivity analyses, but the potential source of heterogeneity could not be clearly identified. Indeed, among the proportion meta-analyses, a statistically significant heterogeneity is often unavoidable [70, 5]. Second, the follow-up duration was different among these included studies. Third, all but one included study was from China and even that study was also from its neighboring country. Thus, the present findings might be more appropriate for the Chinese population or Asian population and it remains to be seen whether our findings can be generalized to European or American populations. In the future, it will be interesting to conduct a similar systematic review with papers that are likely to be forthcoming from Europe and America. However, at the time of writing this meta-analysis, the papers from Europe and America have yet to appear in the literature. Fourth, most of these included studies were retrospective, which might cause a recall bias, especially about data entry. Fifth, abnormal liver biochemical test, rather than liver injury, was assessed, because the definition of liver injury was unclear or inconsistent among these included studies.

In conclusion, abnormal liver biochemistry, primarily characterized as decreased ALB and elevated GGT, AST, and ALT, is common in COVID-19 patients. Abnormal liver biochemical indicators are closely related to the severity and prognosis of COVID-19 patients. Additionally, a higher incidence of abnormal liver biochemistry in COVID-19 patients during hospitalization warrants that liver biochemical tests should be closely monitored and timely measures should be taken. In future, it is necessary to extrapolate these findings to patients who have advanced chronic liver diseases or liver cirrhosis, because there is a potential chance for co-incidental COVID-19 infection to result in hepatic decompensation in patients with little hepatic reserve.

Authors' contributions Conceptualization: XQ; Methodology: YW, HL, XG, and XQ; Validation: XQ, XG, and HL; Formal analysis: YW, HL, XG, and XQ; Investigation: YW, HL, XG, EMY, NM-S, GBLS, RT, FGR, AS, and XQ; Data curation: YW, HL, and XQ; Writing–original draft: YW and XQ; Writing–review and editing: YW, HL, XG, EMY, NM-S, GBLS, RT, FGR, AS, and XQ; Supervision: XQ; Project administration: XQ.

Compliance with ethical standards

References

1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 6 May 2020
2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5(4):536–544
3. Wu Y, Li H, Xu X, Zheng K, Qi X, Guo X. Clinical characteristics and outcomes of 2019 novel coronavirus pneumonia: a meta-analysis (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(3):240–246
4. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40(5):998–1004
5. Chinese Digestion Association, Chinese Medical Doctor Association; Chinese Society of Hepatology, Chinese Medical Association. The protocol for prevention, diagnosis and treatment of liver injury in coronavirus disease 2019 (Article in Chinese) Zhonghua Gan Zang Bing Za Zhi 2020;28(3):217–21
6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8
7. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020. Preprinted. https://doi.org/10.1101/2020.02.03.931766. Accessed 25 Mar 2020
8. Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):97–99
9. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–422
10. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733
11. Yang L, Wang W, Wang X, Zhao J, Xiao L, Gui W, et al. Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice. Hepatology 2019;69(1):294–313
12. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2(3):100113
13. Méndez-Sánchez N, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, et al. What has the COVID-19 pandemic taught us so far? Addressing the problem from a hepatologist's perspective. J Clin Transl Hepatol 2020;8(2):0024
14. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020. https://doi.org/10.1101/2020.02.26.20028191. Accessed 25 Mar 2020
15. Li C, Li M, Gan L, Zhang Y, Lei C. Heart and liver damages in coronavirus sisease-2019 (Article in Chinese). Guangdong Med J 2020;41(9):874–877
16. Li D, Long Y, Huang P, Guo W, Wu S, Zhou Q, et al. Clinical characteristics of 80 patients with COVID-19 in Zhuzhou City (Article in Chinese). Chin J Infect Control 2020;19(3):1–7
17. Qi D, Yan X, Tang X, Yan X, Tang X, Peng J, et al. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. Lancet Respir Med 2020. https://ssrn.com/abstract=3546122. Accessed 6 Apr 2020
18. Sun D, Lv G. Related factors and clinical significance of liver function damage in patients with COVID-19 (Article in Chinese). Chin J Dig Sur 2020. http://rs.yiigle.com/yufabiao/1189815.htm. Accessed 6 Apr 2020
19. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720
20. Wang G, Wu C, Zhang Q, Zhang Q, Wu F, Yu B, et al. Epidemiological and Clinical Features of Corona Virus Disease 2019 (COVID-19) in Changsha, China. Lancet Infect Dis 2020. https://ssrn.com/abstract=3548770. Accessed 6 Apr 2020
21. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506
22. Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv 2020. https://doi.org/10.1101/2020022720029009
23. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69(6):1002–1009
24. Wen K, Li W, Zhang D, Zhang A, Zhang T, Zhao P, et al. Epidemiological and clinical characteristics of 46 newly-admitted coronavirus disease 2019 cases in Beijing (Article in Chinese). Zhonghua Chuan Ran Bing Za Zhi 2020. http://rs.yiigle.com/yufabiao/1182702.htm. Accessed 6 Apr 2020
25. Yang K, Ren M, Xiao L, Liu Y, Shi D, Lu H, et al. Epidemiological and clinical characteristics of 57 cases of new coronavirus pneumonia in non-epidemic areas (Article in Chinese). J Third Milit Med Univ 2020; 1–5
26. Cheng K, Wei M, Shen H, Wu C, Chen D, Xiong W, et al. Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019 (Article in Chinese). Shanghai Med J 2020; 1–15
27. Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):148–152
28. Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2020;43(3):209–214
29. Xu M, Li M, Zhan W, Han T, Liu L, Zhang G, et al. Clinical analysis of 23 cases of 2019 novel coronavirus infection in Xinyang City, Henan Province (Article in Chinese). Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020;32(2):421–425
30. Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(3):229–233
31. Zhao R, Liang Y, Lin Y, Lu L, Li Q, Li Y, et al. Clinical characteristics of 28 patients with novel coronavirus pneumonia (Article in Chinese). Zhonghua Chuan Ran Bing Za Zhi 2020. https://doi.

org/10.3760/cma.j.issn.1000-6680.2020.02.000. Accessed 6 Feb 2020

32. Wang S, Han P, Xiao F, Huang X, Cao L, Zhou Z, et al. Manifestations of liver injury in 333 hospitalized patients with coronavirus disease 2019 (Article in Chinese). Chin J Dig 2020;40(3). https://doi.org/10.3760/cma.j.issn.0254-1432.2020.03.000

33. Zhong S, Lin F, Shi L. The clinical characteristics and outcome of 62 patients with COVID-19 (Article in Chinese). Med J Chin People's Liber Army 2020;45(4):370–374

34. Xiang T, Liu J, Xu F, Cheng N, Liu Y, Qian K, et al. Analysis of clinical characteristics of 49 patients with Novel Coronavirus Pneumonia in Jiangxi province (Article in Chinese). Chin J Respir Crit Care Med 2020;19(2):1–7

35. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 2020;92(7):797–806

36. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606

37. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020;80(4):388–393

38. Yao N, Wang SN, Lian JQ, Sun YT, Zhang GF, Kang WZ, et al. Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28:E003. https://doi.org/10.3760/cma.j.cn501113-20200226-00070

39. Ma Y, Xia S, Wang M, Zhang S, Du W, Chen Q, et al. Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases (Article in Chinese). Zhongguo Dang Dai Er Ke Za Zhi 2020;22(4):1–4

40. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323(15):1488–1494

41. Zhou Y, Zhu C, Wan X, Feng C. Clinical characteristics and laboratory results of 3886 patients with fever and cough (Article in Chinese). Lab Med Clin 2020;17(11):1541–1545

42. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020;ciaa247. https://doi.org/10.1093/cid/ciaa247

43. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55(5):2000524

44. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80(6):639–645

45. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int 2020;40(6):1321–1326

46. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115(5):766–773

47. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020. https://doi.org/10.1016/j.jhep.2020.04.006

48. Sun C, Zhang XB, Dai Y, Xu XZ, Zhao J. Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi

2020;43:E042. https://doi.org/10.3760/cma.j.cn112147-20200224-00168

49. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020;24(6):3404–3410

50. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21(1):74

51. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020. https://doi.org/10.1111/liv.14455

52. Fang XW, Mei Q, Yang TJ, Zhang L, Yang Y, Wang YZ, et al. Clinical characteristics and treatment strategies of 79 patients with COVID-19 (Article in Chinese). Chin Pharmacol Bull 2020;36(04):453–459

53. Li GM, Pan X. Features of liver injury in patients with coronavirus disease 2019 in Bozhou, China (Article in Chinese). J Clin Hepatol 2020;36(4):772–774

54. Wang XF, Zhou ZQ, Yang HH, Tian F, Wang CF, Cui GZ, et al. Extrapulmonary organ damage and clinical significance in patients with coronavirus disease 2019 (Article in Chinese). Zhejiang Med 2020;42(5):485–488 (+96)

55. Yuan J, Sun YY, Zuo YJ, Chen TY, Cao Q, Yuan GD, et al. A retrospective analysis of the clinical characteristica of 223 NCP patients in Chongqing (Article in Chinese). J Southwest Univ (Natural Science Edition) 2020;42(3):17–24

56. Bai P, He W, Zhang X, Liu S, Jin J. Analysis of clinical features of 58 patients with severe or critical 2019 novel coronavirus pneumonia (Article in Chinese). Zhonghua Ji Zhen Yi Xue Za Zhi 2020;4:483–487

57. Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. Lancet Respira Med 2020. https://ssrn.com/abstract=3548785. Accessed 25 Mar 2020

58. Li L, Li S, Xu M, Yu P, Zheng S, Duan Z, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv 2020. https://doi.org/10.1101/2020.02.28.20028514

59. Jeong H, Min S, Chae H, Kim S, Lee G, Namgoong SK, et al. Chloroquine and lopinavir (COVID-19 Drug Candidates) signal amplification by reversible exchange. ChemRxiv 2020. https://www.researchgate.net/publication/340387695_Chloroquine_and_Lopinavir_COVID-19_Drug_Candidates_Signal_Amplification_by_Reversible_Exchange. Accessed 6 Apr 2020

60. Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV -associated tuberculosis in Vietnam. PLoS One 2014;9(1):e84866

61. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007;11(3):525–548 (vi)

62. Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):100–106

63. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38(1):1–9

64. Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang XZ, Wang WJ, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key

mediator of hepatic ischemia-reperfusion injury. Nat Med 2018;24(1):73–83

65. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148(7):1340–1352e7

66. Giner GV, Oltra M, Rueda D. Esteban MJ, Redón J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connnective tissue disease. Clin Rheumatol 2007;26:971–972

67. Chen D, Yang F, Luo Z, Xie H, Dong H, Jia L. Current status and bottle-necks of global pharmaceutical developments against COVID-19 (Article in Chinese). Chin Pharmacol Bull 2020;36(4):1–11

68. Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, et al. Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigi-lance database. Clin Res Hepatol Gastroenterol 2020; p. S2210-7401(19)30270-0

69. Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis. Liver Int 2020;40(6):1316–1320

70. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84

71. Li Y, De Stefano V, Li H, Zheng K, Bai Z, Guo X, et al. Epidemiology of Budd-Chiari syndrome: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019;43(4):468–474

Affiliations

Yanyan Wu[1,2] · Hongyu Li[1] · Xiaozhong Guo[1] · Eric M. Yoshida[3] · Nahum Mendez-Sanchez[4] · Giovanni Battista Levi Sandri[5] · Rolf Teschke[6] · Fernando Gomes Romeiro[7] · Akash Shukla[8] · Xingshun Qi[1]

Yanyan Wu
2963013648@qq.com

Hongyu Li
13309887041@163.com

Xiaozhong Guo
guo_xiao_zhong@126.com

Eric M. Yoshida
emyoshida@shaw.ca

Nahum Mendez-Sanchez
nmendez@medicasur.org.mx

Giovanni Battista Levi Sandri
gblevisandri@gmail.com

Rolf Teschke
rolf.teschke@gmx.de

Fernando Gomes Romeiro
fgromeiro@gmail.com

Akash Shukla
drakashshukla@yahoo.com

1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, People's Republic of China

2   Postgraduate College, Jinzhou Medical University, Jinzhou, People's Republic of China

3   Division of Gastroenterology, Vancouver General Hospital, Vancouver, Canada

4   Liver Research Unit Medica Sur Clinic and Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

5   Department of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy

6   Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Hanau, Germany

7   Faculdade de Medicina de Botucatu, UNESP, Campus de Botucatu, Botucatu, Brazil

8   Department of Gastroenterology, Seth G S Medical College and K E M Hospital, Parel, Mumbai, India